Medication Monitor

Generic Name (Trade Name—Company)
May 13, 2011


(Victrelis—Schering, Merck)
Oral agent for treatment of chronic hepatitis C infection


Treatment of chronic hepatitis C virus (HCV) genotype 1 infection in adult patients with compensated liver disease, including those with cirrhosis

Boceprevir, the first HCV protease inhibitor to reach the U.S. market, is used only in combination with peginterferon alfa and ribavirin. In clinical studies of patients poorly responsive to interferon, oral boceprevir administered three times daily (every 7–9 hours) with food improved the sustained virologic response (SVR) rate by threefold (up to 66%, compared with 23% with placebo). In treatment-naive patients, the SVR was also in the 66% range, compared with 38% for patients in a control group. In combination boceprevir therapy, the most commonly reported adverse reactions (greater than 35%) have been fatigue, anemia, nausea, headache, and dysgeusia.